Vyvanse and Hormonal Contraceptives: What You Need to Know About This Drug Interaction

How Vyvanse Works in the Body

Vyvanse is an inactive prodrug. After oral ingestion, red blood cell hydrolases convert lisdexamfetamine into d-amphetamine and l-lysine. The d-amphetamine is the pharmacologically active molecule: it reverses dopamine and norepinephrine transporters, flooding the synapse with catecholamines. The FDA prescribing information for Vyvanse confirms that the prodrug design was intended to reduce abuse potential compared with immediate-release amphetamine salts. [1]

Absorption and Distribution

Peak plasma concentration (Tmax) of d-amphetamine occurs roughly 3.8 hours after an oral dose. The volume of distribution is large (3.5 to 4.6 L/kg), meaning d-amphetamine distributes widely into tissues including the central nervous system. Protein binding is approximately 20%, which is low enough that protein-displacement interactions with contraceptive hormones are not clinically meaningful.

Metabolism and Elimination

D-amphetamine is metabolized primarily by monoamine oxidase (MAO) and, to a smaller degree, by CYP2D6. Roughly 33 to 46% of a dose is excreted unchanged in urine. This renal excretion step is where the most clinically relevant pharmacokinetic interaction with hormonal contraceptives enters the picture, because urine pH governs how much d-amphetamine is reabsorbed in the renal tubule versus lost in the urine. An alkaline urine pH (above 7) favors reabsorption and raises plasma amphetamine levels; an acidic pH (below 6) favors elimination. [2]

How Hormonal Contraceptives Work and Which Formulations Matter

Hormonal contraceptives are not a single drug. They span combined estrogen-progestin pills, progestin-only pills ("mini-pill"), hormonal IUDs (levonorgestrel), the etonogestrel implant (Nexplanon), combined patches (norelgestromin plus ethinyl estradiol), vaginal rings (NuvaRing, Annovera), and injectable depot medroxyprogesterone acetate (DMPA, Depo-Provera). Each formulation differs in estrogen dose, progestin type, and route of administration. These differences matter when assessing the Vyvanse interaction. [3]

Combined Estrogen-Progestin Methods

Ethinyl estradiol (EE) is the most common synthetic estrogen in combined oral contraceptives (COCs). Standard modern COCs contain 20 to 35 mcg EE per tablet. EE is a known weak inhibitor of CYP2D6, one of the enzymes that contributes to d-amphetamine metabolism. A 2014 pharmacokinetic study in healthy volunteers found that CYP2D6 inhibition by EE at standard oral contraceptive doses is modest compared with dedicated CYP2D6 inhibitors such as paroxetine, but the effect is real. [4]

Progestin-Only Methods

Progestin-only pills, the levonorgestrel IUD (Mirena, Kyleena), and the etonogestrel implant deliver minimal systemic estrogen. Their CYP2D6 inhibitory effect is negligible. Patients on progestin-only methods are therefore least likely to experience a pharmacokinetic change in d-amphetamine plasma levels.

Depot Medroxyprogesterone Acetate

DMPA (150 mg IM every 3 months) delivers high systemic progestin with no estrogen. DMPA is unlikely to alter d-amphetamine clearance meaningfully. One consideration unique to DMPA is its documented effect on mood and dopaminergic tone in some patients, which could confound ADHD symptom tracking independent of any Vyvanse pharmacokinetics. [5]

The Pharmacokinetic Interaction: Estrogen, CYP2D6, and Urinary pH

Three distinct pharmacokinetic mechanisms connect Vyvanse to hormonal contraceptives. None alone rises to a major DDI classification, but they can add up in a specific patient.

CYP2D6 Inhibition by Estrogen

D-amphetamine is a minor CYP2D6 substrate. Ethinyl estradiol inhibits CYP2D6 with a Ki of roughly 18 to 22 µM in vitro, which translates to a weak in vivo effect. A Vyvanse patient switching from a progestin-only IUD to a 30-mcg EE COC might see a modest rise in d-amphetamine area under the curve (AUC). This is unlikely to be clinically dramatic, but it could tip a well-controlled patient toward jitteriness, insomnia, or appetite suppression at a dose that was previously well-tolerated. [4]

Urinary pH and Renal Reabsorption

Estrogen metabolites can mildly alkalinize urine in some individuals. Alkaline urine increases the non-ionized fraction of d-amphetamine, promoting passive tubular reabsorption and raising plasma levels. The FDA label for Vyvanse lists urinary alkalinizers (sodium bicarbonate, acetazolamide) as agents that increase amphetamine blood levels and recommends dose reduction if co-administration is unavoidable. Estrogen's pH effect is far smaller than a pharmaceutical alkalinizer, but the mechanism is identical. [1]

Protein Binding: Not a Concern

Because d-amphetamine's protein binding is only about 20%, displacement interactions with the highly protein-bound steroid hormones (sex hormone-binding globulin carriers) are not clinically meaningful. This mechanism can be excluded from the interaction picture.

The Pharmacodynamic Interaction: Cardiovascular and Neuroendocrine Effects

Beyond pharmacokinetics, both drugs act on overlapping physiologic systems. This is where the more clinically pressing concern lives for most patients.

Blood Pressure and Heart Rate

Vyvanse raises blood pressure and heart rate through increased sympathetic tone. In the key ADHD trials submitted to the FDA, d-amphetamine salts raised mean systolic blood pressure by approximately 2 to 5 mmHg and mean heart rate by 3 to 6 beats per minute compared with placebo. [1] Combined oral contraceptives raise systolic blood pressure by a mean of 8 mmHg and diastolic pressure by 6 mmHg on average, as documented in a Cochrane systematic review of COC cardiovascular effects. [6]

A patient on both agents thus carries additive cardiovascular load. The 2019 American Heart Association scientific statement on stimulant medications in adults notes that baseline and periodic blood pressure monitoring is appropriate whenever a stimulant is prescribed to a patient with any additional cardiovascular risk factor. [7]

HPA Axis and Gonadotropin Signaling

D-amphetamine stimulates corticotropin-releasing hormone (CRH) and cortisol secretion acutely. Estrogen modulates the hypothalamic-pituitary-adrenal (HPA) axis by upregulating CRH gene expression. The combined effect can amplify cortisol reactivity in some women. This does not constitute a dangerous drug interaction in most healthy patients, but it may manifest as heightened anxiety, disrupted sleep, or exaggerated stress response in patients who are already cortisol-sensitive. A 2021 PNAS study (N=120) found that women using COCs showed blunted HPA axis recovery after a standardized stressor, while simultaneously exhibiting higher baseline cortisol than non-users. [8]

ADHD Symptom Perception Across the Menstrual Cycle

Estrogen facilitates dopamine transmission in the prefrontal cortex. Patients cycling naturally often report that ADHD symptoms worsen during the low-estrogen late-luteal phase (days 21 to 28). COCs suppress this natural hormonal fluctuation by maintaining near-constant synthetic estrogen. Some patients on COCs therefore report more consistent Vyvanse efficacy across the month, while others find that the synthetic hormone environment reduces the amplitude of their natural dopaminergic cycles in a way that feels flat. This is an area of active research rather than settled pharmacology. [9]

Specific Contraceptive Formulations: A Practical Risk Stratification

Not all contraceptive methods carry the same interaction potential with Vyvanse. The table below stratifies by formulation and interaction likelihood.

| Contraceptive Method | Estrogen Dose | CYP2D6 Inhibition | BP Effect | Interaction Likelihood | |---|---|---|---|---| | Combined pill (30 to 35 mcg EE) | Moderate | Weak | Moderate | Low-moderate | | Combined pill (20 mcg EE) | Low | Minimal | Mild | Low | | Combined patch (norelgestromin/EE) | Moderate | Weak | Moderate | Low-moderate | | Vaginal ring (etonogestrel/EE) | Low-moderate | Minimal-weak | Mild | Low | | Progestin-only pill | None | Negligible | Negligible | Very low | | Levonorgestrel IUD | Minimal systemic | Negligible | Negligible | Very low | | Etonogestrel implant | None | Negligible | Negligible | Very low | | DMPA injection | None | Negligible | Negligible | Very low |

Patients on higher-EE combined methods who notice any change in Vyvanse tolerability after starting or stopping contraception should report this to their prescriber. A one-step dose adjustment (e.g., from 50 mg to 40 mg lisdexamfetamine) may restore the prior balance without requiring a contraceptive switch.

What the FDA Labels Say

The current Vyvanse FDA prescribing information (2023) lists no specific contraindication to concurrent hormonal contraceptive use. It does state: "Urinary pH affects amphetamine excretion. Acidifying agents lower blood levels; alkalinizing agents raise them." [1] The label also lists cardiovascular risk as a class warning for all amphetamines.

The FDA labeling for combined oral contraceptives (for example, the Yaz prescribing information) does not list amphetamines as a contraindicated co-medication, but does note the blood pressure risk and recommend against COC use in patients with uncontrolled hypertension. [10]

Taken together, the FDA framework treats this as a clinician-managed risk rather than a hard stop.

What Clinical Guidelines Recommend

No major guideline directly addresses the Vyvanse-hormonal contraceptive pairing as a named interaction. However, adjacent guidance is instructive.

The 2023 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Combined Hormonal Contraceptives states: "Combined hormonal contraceptives are contraindicated in women with uncontrolled hypertension (systolic blood pressure 160 mm Hg or higher or diastolic blood pressure 100 mm Hg or higher)." [11] Patients whose blood pressure is driven above this threshold by Vyvanse use should not be started on COCs until blood pressure is controlled.

The 2022 Centers for Disease Control and Prevention U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC) assigns COC use a Category 3 or 4 (relative or absolute contraindication) in the presence of adequately or inadequately controlled hypertension, respectively. [12] Prescribers managing both a stimulant and a COC should check blood pressure at each visit and document the clinical reasoning.

The American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter for ADHD recommends baseline vital signs and follow-up cardiovascular monitoring for all stimulant prescriptions, without specific mention of hormonal contraceptives. [13]

Monitoring Protocol for Patients on Both Medications

Baseline Assessment

Before starting either medication in a patient already taking the other, the clinician should record:

• Sitting and standing blood pressure (both arms if first measurement)
• Resting heart rate
• Weight and BMI
• Current contraceptive formulation (name, dose, route)
• Vyvanse dose and time of day taken
• History of migraines with aura (a contraindication to COC independent of stimulants)

Follow-Up Schedule

Blood pressure and heart rate should be re-checked 4 to 8 weeks after initiating or changing either agent. If systolic blood pressure rises above 140 mmHg on two separate readings, the prescriber should reassess both medications. Switching from a combined hormonal method to a progestin-only method is a reasonable first step before reducing the Vyvanse dose, as it removes the estrogen-driven blood pressure contribution without compromising contraceptive efficacy.

Symptom Diary

Patients should be counseled to track ADHD symptom control, sleep quality, and appetite across their pill cycle (or across the ring/patch cycle). Changes in symptom control timed to contraceptive phase may indicate a pharmacodynamic interaction worth addressing.

Patient Counseling Points

Prescribers and clinical pharmacists should cover the following with any patient taking both Vyvanse and a hormonal contraceptive:

1. Neither drug makes the other less effective at its primary purpose. Vyvanse does not reduce contraceptive efficacy. Hormonal contraceptives do not block the ADHD benefit of Vyvanse. The interaction is about side-effect overlap and minor pharmacokinetic changes, not efficacy cancellation.

2. If you switch from a progestin-only method to a combined pill or patch, watch for new or worsened jitteriness, insomnia, or appetite loss in the first two to four weeks. These symptoms could reflect a modest rise in d-amphetamine exposure.

3. Blood pressure is the most clinically important monitoring target. Check it at home with a validated cuff if your prescriber recommends it, and report any reading above 140/90 mmHg.

4. Do not self-adjust your Vyvanse dose based on perceived hormonal changes without speaking to your prescriber. Dose titration in ADHD is based on response and tolerability at a given point in time, not on a formula.

5. Women with migraines with aura should not use combined hormonal contraceptives regardless of Vyvanse co-use. This is an independent ACOG contraindication. [11]

Special Populations

Adolescents

Adolescent girls represent a significant portion of both the ADHD-diagnosed population and hormonal contraceptive users. A 2020 CDC National Survey of Family Growth found that 19.5% of females aged 15 to 19 used hormonal contraception. [12] The ADHD prevalence in this group is estimated at 6 to 9%. The blood pressure and HPA axis concerns discussed above apply equally to adolescents.

Perimenopausal Women

Women in perimenopause may use low-dose COCs for both contraception and symptom management while continuing ADHD treatment. Estrogen fluctuations in perimenopause are already large; adding the dopaminergic and adrenergic effects of amphetamine can amplify mood instability. Progestin-only methods or low-dose transdermal estrogen (which has a more stable delivery profile than oral EE) may produce a smoother pharmacodynamic picture in this group.

Patients With Binge Eating Disorder

Vyvanse is FDA-approved for moderate-to-severe BED at 50 to 70 mg daily. Women with BED have a higher prevalence of polycystic ovary syndrome (PCOS) and irregular cycles. Hormonal contraceptives are often co-prescribed in this group for cycle regulation. The interaction considerations are identical to those in ADHD patients; no additional BED-specific pharmacokinetic data exist. [1]

Key Research Gaps

The evidence base for this specific drug pair is thin. No dedicated pharmacokinetic trial has examined lisdexamfetamine co-administration with hormonal contraceptives in a controlled crossover design. Most clinical guidance extrapolates from:

• General amphetamine pharmacokinetics (urinary pH studies conducted decades ago)
• CYP2D6 in vitro inhibition data for ethinyl estradiol
• Cardiovascular data from COC and stimulant trials conducted separately

A prospective study measuring d-amphetamine AUC in women before and after initiation of a 30-mcg EE COC would fill this gap directly. Absence of such data means clinicians are managing this interaction on mechanistic inference and case-level clinical experience rather than trial-level evidence.